Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.992.892 €): PancREatic Cancer OrganoiDs rEsearch Network Hor28.08.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
PancREatic Cancer OrganoiDs rEsearch Network
The PRECODE Network (PancREatic Cancer OrganoiDs rEsearch) central mission is to establish pancreatic organoid research firmly in the European Union, by training the next generation of creative and innovative researchers in pancreatic cancer. This will be done through a shared doctorate program of excellence that fulfils the three “I”: international, interdisciplinary and intersectorial. Organoids can be viewed as small micro-organs which can recapitulate the organization and the function thereof. As micro-organs organoids can be used to reduce animal experiments and help to reach 3R goals. Organoids from pancreatic cancer will help us to learn which drugs might help in the therapy of this terrible disease. They can be isolated from a variety of clinical sources with minimal material needed. This makes them a perfect tool for precision medicine. Sequencing, metabolomics and high throughput in vitro experiments to deduct the best possible drug combination fit hand in glove with this approach. Training of ESRs will be achieved by e-learning, workshops and secondments. They will earn to cultivate and manipulate organoids as well as cutting edge molecular biology techniques. Therefore our work group consists of 15 beneficiaries and 7 partner organization (including three patient advocate groups from Sweden, Italy and Germany) to develop those technologies and to train ESRs in their application. PRECODE will therefore connect the concepts of investigation, education and innovation establishing a capacitation for the ESRs that goes beyond the state of the art and that will allow them to improve their competences and their professional career at the same time that we advance towards innovation in the field of pancreatic cancer research.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Astrazeneca UK Ltd. | 303.173 € |
| Cellphenomics GmbH | 252.788 € |
| Friedrich-Alexander-Universitaet Erlangen-Nuernberg | 252.788 € |
| Gdanski Uniwersytet Medyczny | 227.479 € |
| Karolinska Institutet | 281.983 € |
| Klinikum DER Technischen Universität München (TUM Klinikum) | 252.788 € |
| Mimetas B.V. | 265.620 € |
| Stichting Amsterdam UMC | 265.620 € |
| The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | 274.684 € |
| Umea Universitet | 281.983 € |
| Universidad de Navarra | 250.905 € |
| Universita Degli Studi Di Verona | 261.500 € |
| Universitatsklinikum Erlangen | 252.788 € |
| Universiteit Leiden | 265.620 € |
| University of Glasgow | 303.173 € |
Quelle: https://cordis.europa.eu/project/id/861196
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.